Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1417944 | 0.98 | CA12 (0.47) | CA12CA1CA2CA9CYP1A2 | |
| Hydrochloric Acid SCHEMBL22807263 | 0.98 | CA12 (0.47) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL1418369 | 0.89 | CYP1A2 (0.55) | CA12CA1CA2CA9CYP1A2 | |
| Hydrochloric Acid SCHEMBL1417999 | 0.87 | CYP1A2 (0.53) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL23583339 | 0.84 | CYP1A2 (0.59) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL19317379 | 0.83 | CA12 (0.52) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL12589581 | 0.83 | CA12 (0.59) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL26290534 | 0.82 | LTA4H (0.45) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL9830045 | 0.82 | MEN1 (0.52) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL16914705 | 0.82 | CA12 (0.50) | CA12CA1CA2CA9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116003400-B | 2-Formyl tetrahydronaphthyridine compound and medicinal composition and application thereof | 暨南大学 | 2025-05-02 | — | — | CN | disclosed |
| CN-116102549-B | 5-Aldehyde heterocyclic amide compound and application thereof | 暨南大学 | 2025-02-11 | — | — | CN | disclosed |
| EP-3663285-B1 | FORMYLPYRIDINE DERIVATIVE HAVING FGFR4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023082044-A1 | 5-FORMYL HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | 暨南大学 | 2023-05-19 | — | — | WO | disclosed |
| WO-2023082044-A1 | 5-FORMYL HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | 暨南大学 | 2023-05-19 | — | — | WO | disclosed |
| CN-116102549-A | 5-aldehyde heterocyclic amide compound and application thereof | 暨南大学 | 2023-05-12 | — | — | CN | disclosed |
| US-20230012600-A1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVES AND USES THEREOF | BROADENBIO CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| US-11312701-B2 | Formylpyridine derivative having FGFR4 inhibitory activity, preparation method therefor and use thereof | ABBISKO THERAPEUTICS CO., LTD (CN) | 2022-04-26 | — | — | US | disclosed |
| US-20220119386-A1 | FUSED RING DERIVATIVE USED AS FGFR4 INHIBITOR | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2022-04-21 | — | — | US | disclosed |
| US-11136320-B2 | Fused ring derivative used as FGFR4 inhibitor | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-10-05 | — | — | US | disclosed |
| EP-3663285-A1 | FORMYLPYRIDINE DERIVATIVE HAVING FGFR4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2020-06-10 | — | — | EP | disclosed |
| WO-2020020377-A1 | FUSED RING DERIVATIVE USED AS FGFR4 INHIBITOR | 北京加科思新药研发有限公司 | 2020-01-30 | — | — | WO | disclosed |
| WO-2019057053-A1 | FUSED RING DERIVATIVE USED AS FGFR4 INHIBITOR | 北京加科思益新药研发有限公司 | 2019-03-28 | — | — | WO | disclosed |
| CN-102985438-B | As the C-28 acid amides of the modified C-3 betulinic acid derivative of the ripe inhibitor of HIV | BRISTOL-MYERS SQUIBB CO. (US) | 2016-05-18 | — | — | CN | disclosed |
| EP-2576586-B1 | C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8802661-B2 | C-28 amides of modified C-3 betulinic acid derivatives as HIV maturation inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-12 | — | — | US | disclosed |
| EP-2576586-A1 | C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | Bristol-Myers Squibb Company (US) | 2013-04-10 | — | — | EP | disclosed |
| CN-102985438-A | C-28 amides of modified C-3 betulinic acid derivatives as HIV maturation inhibitors | BRISTOL MYERS SQUIBB CO | 2013-03-20 | — | — | CN | disclosed |
| US-20120142653-A1 | C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| WO-2011153319-A1 | C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312701-B2 | Formylpyridine derivative having FGFR4 inhibitory activity, preparation method therefor and use thereof | FGFR4, FGFR1, FGFR2 | CA12 4234/4885CA1 3805/4885CA2 4161/4885 |
| US-11136320-B2 | Fused ring derivative used as FGFR4 inhibitor | FGFR4, FGFR1, FGFR3 | CA12 4435/4885CA1 4485/4885CA2 2879/4885 |
| US-20220119386-A1 | FUSED RING DERIVATIVE USED AS FGFR4 INHIBITOR | FGFR4, FGFR1, FGFR3 | CA12 4435/4885CA1 4485/4885CA2 2879/4885 |
| US-20120142653-A1 | C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | ERG28, BET1, BRD3 | CA12 1903/4885CA1 3214/4885CA2 2919/4885 |
| US-20230012600-A1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVES AND USES THEREOF | FGFR4, FGFR1, FGFR3 | CA12 3173/4885CA1 2722/4885CA2 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.